Poly ADP-ribose polymerase inhibitors (PARPi) are used for patients with advanced prostate cancer bearing alterations in homologous recombination repair (HRR) genes. We sought to characterize HRR gene ...

Akeega, an oral dual mechanism therapy pairing niraparib with abiraterone, has won a positive committee opinion in Europe for men with early metastatic prostate cancer and DNA repair mutations.

The phase III PROfound study enrolled patients with mCRPC harboring DNA repair alterations who had progressed on at least one AR-pathway inhibitor (ARPI) and randomly assigned them to olaparib versus ...

Identification of variants influences treatment decisions. Inhibitors of the poly-ADP-ribose polymerase (PARP) system, a pathway for repairing single-stranded DNA breaks, are recommended for tumors ...

"Men with these known variants should be counseled on the increased risk of prostate cancer, and I would recommend that they undergo regular PSA screening…Of course there are many other factors that ...